Creating Incentives To Narrow The Gap In Health Outcomes: Expanding Value Assessment To Incorporate Health Inequality

Adding to the ongoing national dialogue on racial inequality, PRECISIONheor’s Jason Shafin and Meena Venkatachalam join the conversation in their Health Affairs blog post: “Creating Incentives To Narrow The Gap In Health Outcomes: Expanding Value Assessment To Incorporate Health Inequality”.

LEARN MORE

Creating Incentives To Narrow The Gap In Health Outcomes: Expanding Value Assessment To Incorporate Health Inequality2020-08-06T12:40:59-04:00

COVID-19 Pandemic Vindicates the ISPOR Value Flower

ISPOR's “value flower” versus the traditional QALYs approach: Precision's Jason Shafrin, Kathy Lang and Ross Maclean discuss why the “value flower” model can more accurately value treatments - in cases like COVID-19 - which have a transformational impact on the lives of not only of patients, but also caregivers, employers, and broader society.

LEARN MORE

COVID-19 Pandemic Vindicates the ISPOR Value Flower2020-07-17T15:19:36-04:00

The role of COVID-19 antibody testing for employers

As employers consider including COVID-19 testing as part of their reopening plans, Precision experts Jacquelyn Chou, Caroline Huber and Jennifer Millard discuss the two key issues that must be resolved before antibody testing can be truly useful for an employer.

LEARN MORE

The role of COVID-19 antibody testing for employers2020-05-27T15:45:56-04:00

Drug Pricing and the Broader Quality of Life

By limiting the benefits included in its model and inappropriately valuing these health benefits, ICER risks mispricing innovative health therapies and disincentivizing investments in research and development.

LEARN MORE

Drug Pricing and the Broader Quality of Life2020-02-06T10:26:03-05:00